MOTS-c vs Livagen

MOTS-c and Livagen are both research peptides investigated for overlapping applications in metabolic health and aging, yet they diverge sharply in origin, mechanism, and evidence maturity. MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in 2015, with a well-characterized role in AMPK activation and metabolic regulation, supported by robust preclinical data and a modified analog that has entered Phase 1 trials. Livagen is a synthetic tetrapeptide developed decades earlier, with a proposed mechanism involving chromatin decondensation in hepatocytes, but its clinical evidence is limited to Russian publications. Researchers should weigh the depth of mechanistic understanding and translational progress of MOTS-c against the liver-specific, epigenetic focus of Livagen, noting that the latter's evidence base is narrower and less internationally validated.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome, specifically the 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at the University of Southern California, it functions as a metabolic regulator primarily through AMPK activation, a key cellular energy sensor. In preclinical models, MOTS-c has demonstrated the ability to prevent diet-induced obesity and insulin resistance, enhance exercise capacity—old mice ran twice as long on treadmill tests—and reduce age-related metabolic decline. A modified analog, CB4211, showed good tolerability in a Phase 1 human trial, though no clinical trials of native MOTS-c have been completed. The evidence strength is moderate to high for preclinical efficacy, but human data remain absent for the native peptide, limiting translational confidence.

Livagen (Lys-Glu-Asp-Ala, KEDA) is a synthetic tetrapeptide with a molecular weight of approximately 432.5 g/mol, developed by Russian researcher Vladimir Khavinson as part of a series of tissue-specific bioregulatory peptides. Its proposed mechanism involves decondensing heterochromatin in aged hepatocytes, thereby reactivating genes that become silenced during aging and restoring hepatic function. Published studies, primarily in Russian journals, report effects on chromatin structure and gene expression in aged liver tissue, suggesting a epigenetic rejuvenation approach. Clinical evidence is limited to these Russian publications, with no international replication or large-scale trials. The evidence strength is low to moderate, with mechanistic plausibility but a narrow, geographically confined evidence base that may not meet Western research standards for rigor and reproducibility.

Both MOTS-c and Livagen are investigated for metabolic health, though their approaches differ: MOTS-c targets systemic metabolic regulation via AMPK, while Livagen focuses on hepatic function restoration. Additionally, both peptides are studied in the context of anti-aging. MOTS-c is specifically researched for its exercise mimetic and anti-obesity effects, which may counteract age-related metabolic decline. Livagen is more directly tied to anti-aging and longevity through its proposed chromatin remodeling mechanism in the liver, potentially addressing a key organ in systemic aging. Researchers should note that while the application labels overlap, the underlying biological targets and evidence bases are distinct, making direct comparisons in experimental outcomes challenging without context-specific studies.

For MOTS-c, no adverse effects have been reported in preclinical animal studies, but human tolerability is completely unknown for the native peptide due to the absence of completed human trials. The modified analog CB4211 showed good tolerability in a Phase 1 trial, providing some indirect safety signal. For Livagen, it is reported as well-tolerated in animal studies and limited clinical use, with no serious adverse events documented. Its simple tetrapeptide structure suggests low toxicity, but the lack of rigorous, independent safety assessments—especially in long-term or high-dose contexts—means researchers should exercise caution. Both peptides require further safety characterization, but Livagen's longer history of use in Russian clinical settings offers a slight edge in anecdotal safety data, albeit without robust pharmacokinetic or toxicological profiling.